Synopsis: Wipro, Zydus Lifesciences, Aurobindo Pharma, Cyient, and CMS Info Systems are fundamentally strong companies that have recently announced share buybacks, signaling confidence in future growth.
Share buybacks are often seen as a sign of confidence from a company’s management. When a company repurchases its own shares, it signals that it believes the stock is undervalued and has strong future prospects.
For investors, buybacks can also improve earnings per share and enhance shareholder value. In this article, we look at a few fundamentally strong stocks that have recently announced share buyback programs and what makes them worth watching. Here are a few fundamentally strong stocks that have recently announced share buybacks
Wipro Limited
With a market capitalization of Rs. 1,92,152.61 crore, the shares of Wipro Limited closed at Rs. 182.95 per equity share, rising nearly 0.85 percent from its previous day’s close price of Rs. 181.40.
Wipro Limited has announced a tender offer buyback with a maximum buyback price of Rs. 250 per share and a total buyback size of Rs. 15,000 crore. Shareholders holding shares as of the 5 June 2026 record date were eligible to participate in the buyback. The tendering window remained open from 11 June 2026 to 17 June 2026, allowing eligible investors to submit their shares for buyback consideration.
Wipro Limited is a multinational information technology, consulting, and business process services company headquartered in Bengaluru, India. Established in 1945, it is among India’s leading IT firms and one of the world’s top providers of digital transformation and AI-powered technology solutions, serving clients in over 65 countries.
Coming into financial highlights, Wipro Limited’s revenue has increased from Rs. 22,504 crore in Q4 FY25 to Rs. 24,236 crore in Q4 FY26, which has grown by 7.70 percent. The net profit has decreased by 1.84 percent from Rs. 3,588 crore in Q4 FY25 to Rs. 3,522 crore in Q4 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 17.9 percent and 15.5 percent, respectively. Wipro Limited has an earnings per share (EPS) of Rs. 12.6, and its debt-to-equity ratio is 0.23x.
Zydus Lifesciences Limited
With a market capitalization of Rs. 1,08,698.43 crore, the shares of Zydus Lifesciences Limited closed at Rs. 1,080.25 per equity share, down nearly 0.69 percent from its previous day’s close price of Rs. 1,087.75.
Zydus Lifesciences Limited has announced a tender offer buyback with a maximum buyback price of Rs. 1,260 per share and a total buyback size of Rs. 1,100 crore. Shareholders holding shares as of the 29 May 2026 record date were eligible to participate in the buyback. The tendering window remained open from 4 June 2026 to 10 June 2026, allowing eligible investors to submit their shares for buyback consideration.
Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Formerly known as Cadila Healthcare Limited, it is one of India’s leading generic and specialty drug makers, active across the full pharmaceutical value chain and present in more than 50 countries.
Coming into financial highlights, Zydus Lifesciences Limited’s revenue has increased from Rs. 6,528 crore in Q4 FY25 to Rs. 7,587 crore in Q4 FY26, which has grown by 16.22 percent. The net profit has also grown by 7.79 percent from Rs. 1,244 crore in Q4 FY25 to Rs. 1,341 crore in Q4 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 21.2 percent and 21.2 percent, respectively. Zydus Lifesciences Limited has an earnings per share (EPS) of Rs. 50.1, and its debt-to-equity ratio is 0.46x.
Aurobindo Pharma Limited
With a market capitalization of Rs. 80,960.84 crore, the shares of Aurobindo Pharma Limited closed at Rs. 1393.95 per equity share, down nearly 0.93 percent from its previous day’s close price of Rs. 1,407 per share.
Aurobindo Pharma Limited has announced a tender offer buyback with a maximum buyback price of Rs. 1,475 per share and a total buyback size of Rs. 800 crore. Shareholders holding shares as of the 17 April 2026 record date were eligible to participate in the buyback. The tendering window remained open from 23 April 2026 to 29 April 2026, allowing eligible investors to submit their shares for buyback consideration.
Aurobindo Pharma Limited is a global pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded in 1986, it develops, manufactures, and markets generic and specialty pharmaceuticals along with active pharmaceutical ingredients (APIs). The company is a leading exporter of affordable medicines, operating in more than 150 countries.
Coming into financial highlights, Aurobindo Pharma Limited’s revenue has increased from Rs. 8,382 crore in Q4 FY25 to Rs. 8,853 crore in Q4 FY26, which has grown by 5.62 percent. The net profit has also grown by 1.99 percent from Rs. 903 crore in Q4 FY25 to Rs. 921 crore in Q4 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 12.8 percent and 10.1 percent, respectively. Aurobindo Pharma Limited has an earnings per share (EPS) of Rs. 60.3, and its debt-to-equity ratio is 0.21x.
Cyient Limited
With a market capitalization of Rs. 10,072.23 crore, the shares of Cyient Limited closed at Rs. 906.25 per equity share, rising nearly 1.03 percent from its previous day’s close price of Rs. 897.05.
Cyient Limited has announced a tender offer buyback with a maximum buyback price of Rs. 1,125 per share and a total buyback size of Rs. 720 crore. Shareholders holding shares as of the 17 June 2026 record date were eligible to participate in the buyback. The opening and closing dates of the buyback offer are yet to be announced, and eligible shareholders will be able to tender their shares during the specified offer period.
Cyient Limited is an Indian multinational engineering and technology solutions company headquartered in Hyderabad, Telangana. Founded in 1991 as Infotech Enterprises, it provides design-led manufacturing, digital engineering, geospatial, and analytics services to global industries.
Coming into financial highlights, Cyient Limited’s revenue has increased from Rs. 1,909 crore in Q4 FY25 to Rs. 1,927 crore in Q4 FY26, which has grown by 0.94 percent. The net profit has decreased by 64.52 percent from Rs. 186 crore in Q4 FY25 to Rs. 66 crore in Q4 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 12.3 percent and 8.61 percent, respectively. Cyient Limited has an earnings per share (EPS) of Rs. 38.5, and its debt-to-equity ratio is 0.08x.
CMS Info Systems Limited
With a market capitalization of Rs. 4,860.92 crore, the shares of CMS Info Systems Limited closed at Rs. 295.25 per equity share, down nearly 1.06 percent from its previous day’s close price of Rs. 298.40.
CMS Info Systems Limited has announced a tender offer buyback with a maximum buyback price of Rs. 340 per share and a total buyback size of Rs. 167 crore. Shareholders holding shares as of the 22 May 2026 record date were eligible to participate in the buyback. The tendering window remained open from 29 May 2026 to 4 June 2026, allowing eligible investors to submit their shares for buyback consideration.
CMS Info Systems Limited is an Indian cash management and business services company headquartered in Navi Mumbai, Maharashtra. Founded in 2008, it is among India’s largest cash logistics and technology-enabled business services providers, serving banks, financial institutions, retail chains, and e-commerce firms nationwide.
Coming into financial highlights, CMS Info Systems Limited’s revenue has increased from Rs. 619 crore in Q4 FY25 to Rs. 633 crore in Q4 FY26, which has grown by 2.29 percent. The net profit has decreased by 19.39 percent from Rs. 98 crore in Q4 FY25 to Rs. 79 crore in Q4 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 17.6 percent and 13.2 percent, respectively. CMS Info Systems Limited has an earnings per share (EPS) of Rs. 18.4, and its debt-to-equity ratio is 0.09x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
